SFDA Revises China GMP Guidelines; Seeks Industry Comments On Impact To Local Industry
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA revised its Good Manufacturing Practices Guidelines, and is asking for industry feedback on how the guidelines would affect local pharmaceutical companies, SFDA Deputy Director Wu Zhen said during a forum on drug safety and healthcare reform in Beijing April 28